A first-line drug for abortive therapy in simple migraine is:

Migraine is a neurovascular disorder characterized by episodic headache often accompanied by nausea, photophobia, and phonophobia. Abortive (acute) therapy aims to stop or reduce symptoms once a migraine begins. First-line treatment for mild to moderate or “simple” migraines typically includes nonsteroidal anti-inflammatory drugs (NSAIDs), which reduce prostaglandin-mediated inflammation and pain. Early administration improves effectiveness and may prevent progression of symptoms. Rationale: A. Butalbital/acetaminophen/caffeine (Fioricet) is not considered first-line therapy for migraines due to its risk of dependence, medication-overuse headache, and sedation. It is generally reserved for refractory cases and is not preferred for routine abortive migraine management. Its barbiturate component increases risk of tolerance and rebound headaches. B. Butorphanol nasal spray (Stadol NS) is an opioid agonist-antagonist and is not recommended for first-line migraine therapy. Opioids are generally avoided in migraine management due to high risk of dependence, medication-overuse headaches, and inferior efficacy compared to NSAIDs and triptans. It is reserved only for rare, refractory cases when other treatments fail. C. Naproxen (Aleve) is a first-line abortive treatment for simple migraines because it reduces inflammation and pain by inhibiting cyclooxygenase enzymes and prostaglandin synthesis. It is effective for mild to moderate migraine attacks and is widely recommended due to its safety, accessibility, and efficacy when taken early in the migraine episode. D. Meperidine (Demerol) is not appropriate for migraine management due to its addictive potential and association with poor headache outcomes, including rebound headaches. Opioids are not recommended for routine migraine treatment and are reserved only for exceptional circumstances when other therapies are ineffective or contraindicated.